GlassScriptPhysician profile
Michelle Caneda
NPI 1568047504
$884.53
in general payments reported to CMS, 2019-2025
18 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $80.00 · 2023: $274 · 2024: $200 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $804.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $168.02 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $103.16 | 2022-2023 | |
| Abbvie INC. | $80.51 | 2023-2025 | |
| Glaxosmithkline, LLC. | $76.97 | 2023-2024 | Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $73.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $73.66 | 2023-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $54.45 | 2023-2025 | |
| Inspire Medical Systems, INC. | $42.47 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $29.13 | 2025 | Gardasil 9, Capvaxive |
| Shield Therapeutics INC | $28.21 | 2023-2024 | Accrufer |
| Sumitomo Pharma America, INC. | $27.64 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $23.42 | 2025 | Sunosi |
| Dexcom, INC. | $23.32 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $18.53 | 2024 | Spravato |
| Medtronic, INC. | $16.46 | 2023 | Vanta Adaptivestim |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $16.41 | 2023 | Gvoke Hypopen |
| Exeltis, USA INC. | $14.72 | 2023 | Slynd |
| Astrazeneca Pharmaceuticals LP | $13.76 | 2025 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Caneda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.